Suppr超能文献

HIV 复制能力是未经治疗的慢性 HIV 感染者疾病进展的独立预测因子。

HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

机构信息

Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

出版信息

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):472-9. doi: 10.1097/QAI.0b013e3181cae480.

Abstract

OBJECTIVE

To assess the effect of pol replication capacity (RC) on the hazard ratio of progression to a composite endpoint of time to progression to <350 CD4+ cells per microliter, initiation of therapy, or death.

METHODS

pol RC assays were performed after study closure in baseline samples obtained from 316 enrollees in a prospectively monitored cohort of treatment-naive adults with >or=450 CD4+ cells per microliter and >or=1000 HIV-1 RNA copies per milliliter.

RESULTS

The median RC was 79%. Patients with a lower RC had a lower median viral load (4.0 vs 4.2 Log HIV-1 RNA copies/mL, P = 0.026) and a lower rate of protease inhibitor resistance 2% vs 8%, P = 0.03). Otherwise, baseline demographic and laboratory characteristics were similar. The hazard ratio of progression to the composite endpoint was 0.73 (P = 0.041) for persons with lower RC, 2.07 per 1.0 log10 higher viral load (P < 0.001), and 0.86 per 50 cells per microliter higher CD4+ cell count (P < 0.001). The effect of lower RC was also significant in a separate analysis of time to initiation of therapy (P = 0.04).

CONCLUSIONS

These results show that untreated patients with lower vs higher RC had a slower rate of progression as assessed by a composite outcome of time to CD4+ count <or=350 cells per microliter, treatment initiation, or death.

摘要

目的

评估聚合酶复制能力(RC)对复合终点进展风险比的影响,该终点包括从进展至每微升<350 个 CD4+细胞、开始治疗或死亡的时间、进展至该终点的时间、开始治疗或死亡。

方法

在一项前瞻性监测的、未经治疗的成人队列研究中,在基线时获得了 316 名患者的样本,这些患者的 CD4+细胞计数>450 个/微升,HIV-1 RNA 拷贝数>1000 个/ml,研究结束后进行了 pol RC 检测。

结果

中位 RC 为 79%。RC 较低的患者病毒载量中位数较低(4.0 对 4.2 Log HIV-1 RNA 拷贝/ml,P = 0.026),蛋白酶抑制剂耐药率较低(2%对 8%,P = 0.03)。其他基线人口统计学和实验室特征相似。RC 较低的患者进展为复合终点的风险比为 0.73(P = 0.041),每增加 1.0 log10 病毒载量,风险比为 2.07(P < 0.001),每增加 50 个细胞/微升 CD4+细胞计数,风险比为 0.86(P < 0.001)。在对开始治疗时间的单独分析中,低 RC 的效果也很显著(P = 0.04)。

结论

这些结果表明,未经治疗的患者中,RC 较低的患者与 RC 较高的患者相比,复合终点(进展至每微升<350 个 CD4+细胞、开始治疗或死亡的时间)的进展速度较慢。

相似文献

引用本文的文献

本文引用的文献

9
Human genes that limit AIDS.限制艾滋病的人类基因。
Nat Genet. 2004 Jun;36(6):565-74. doi: 10.1038/ng1369.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验